Segall Bryant & Hamill’s AstraZeneca AZN Stock Holding History

Segall Bryant & Hamill’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,174	Closed	-$311K	–	524
2023 Q2	$311K	Buy	2,174 +118	+6%	+$17.4K	﹤0.01%	637
2023 Q1	$285K	Hold	2,056	–	–	﹤0.01%	649
2022 Q4	$278K	Hold	2,056	–	–	﹤0.01%	657
2022 Q3	$226K	Buy	2,056 +44	+2%	+$5.58K	﹤0.01%	685
2022 Q2	$265K	Sell	2,012 -150	-7%	-$19.7K	﹤0.01%	678
2022 Q1	$287K	Buy	+2,162	New	+$259K	﹤0.01%	684
2021 Q4	–	Sell	-1,954	Closed	-$234K	–	603
2021 Q3	$234K	Buy	1,954 +17	+0.9%	+$1.98K	﹤0.01%	742
2021 Q2	$232K	Sell	1,937 -11,590	-86%	-$1.27M	﹤0.01%	723
2021 Q1	$1.34M	Buy	+13,527	New	+$1.36M	0.01%	517

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Segall Bryant & Hamill's AZN Position: Q3 2023 in Review

Segall Bryant & Hamill sold out of AstraZeneca (AZN) in Q3 2023, closing a stake of 2,174 shares — an estimated $311K sold.

Segall Bryant & Hamill first reported a position in AZN in Q1 2021 and held it in 9 quarters. The position peaked at $1.34M in Q1 2021. 1,073 funds tracked by Wall St. Rank hold AZN as of Q3 2023.

Segall Bryant & Hamill reported no remaining AstraZeneca position as of Q3 2023 after selling out during the quarter.
Segall Bryant & Hamill sold 2,174 AstraZeneca shares in Q3 2023, an estimated $311K.
Segall Bryant & Hamill first reported a position in AstraZeneca in Q1 2021 and held it in 9 quarters.
Segall Bryant & Hamill's AstraZeneca position peaked at $1.34M in Q1 2021.
1,073 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2023.

Based on Segall Bryant & Hamill's 13F filing for Q3 2023, filed 9 Nov 2023.